🔎 Trials Near Me

Utama › Kanser Prostat Rintangan Kastra › Pennsylvania

Kajian klinikal Kanser Prostat Rintangan Kastra di Pennsylvania

5 kajian untuk Kanser Prostat Rintangan Kastra sedang mencari peserta di lokasi di Pennsylvania.

Bandar di Pennsylvania

Teks kajian rasmi (Bahasa Inggeris)

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  • Lehigh Valley Hospital, Allentown
  • MidLantic Urology, Bala-Cynwyd
  • Penn State Milton S. Hershey Medical Center, Hershey
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07225946

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • MidLantic Urology, Bala-Cynwyd
  • Keystone Urology Specialists, Lancaster
  • Penn Medicine Abramson Cancer Center, Philadelphia
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT07164443

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

  • UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06863272

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • Penn State Milton S. Hershey Medical Center, Hershey
  • Thomas Jefferson University Honickman Center, Philadelphia
  • UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 hingga 100 · Lelaki · Dikemas kini 13 Ogo 2026 · NCT05519449

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.